Applied Genetic Technologies Corporation

DB:2GT Stock Report

Market Cap: €12.6m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Applied Genetic Technologies Management

Management criteria checks 1/4

Key information

Sue Washer

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage37.38%
CEO tenure20.8yrs
CEO ownershipn/a
Management average tenure1.5yrs
Board average tenure11.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sue Washer's remuneration changed compared to Applied Genetic Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$70m

Jun 30 2022US$1mUS$551k

-US$69m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021n/an/a

-US$63m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021US$1mUS$530k

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020n/an/a

-US$57m

Sep 30 2020n/an/a

-US$50m

Jun 30 2020US$988kUS$530k

-US$46m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019n/an/a

-US$19m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019US$1mUS$514k

-US$2m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

-US$18m

Sep 30 2018n/an/a

-US$19m

Jun 30 2018US$1mUS$502k

-US$21m

Mar 31 2018n/an/a

-US$18m

Dec 31 2017n/an/a

-US$11m

Sep 30 2017n/an/a

-US$4m

Jun 30 2017US$1mUS$487k

US$407k

Mar 31 2017n/an/a

US$6m

Dec 31 2016n/an/a

US$10m

Sep 30 2016n/an/a

US$11m

Jun 30 2016US$2mUS$464k

-US$1m

Compensation vs Market: Sue's total compensation ($USD1.47M) is above average for companies of similar size in the German market ($USD429.60K).

Compensation vs Earnings: Sue's compensation has increased whilst the company is unprofitable.

CEO

Sue Washer (61 yo)

20.8yrs
Tenure
US$1,473,567
Compensation

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...

Leadership Team

NamePositionTenureCompensationOwnership
Susan Washer
President20.8yrsUS$1.47mno data
Jonathan Lieber
Chief Financial Officer1.3yrsUS$1.00mno data
Susan Schneider
Chief Medical Officer1.1yrsUS$832.63kno data
Nicholas Muzyczka
Co-Founder23.9yrsno datano data
Barry Byrne
Co-Founder23.9yrsno datano data
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datano datano data
Richard Samulski
Co-Founder23.9yrsno datano data
Terence Flotte
Co-Founder23.9yrsno datano data
Gerald Reynolds
Chief Accounting Officer1.5yrsno data0%
€ 0
Abraham Scaria
Chief Scientific Officer1yrno datano data
Hope D'Oyley-Gay
General Counsel1yrno datano data
David Knop
Senior Vice President of Process & Assay Developmentless than a yearUS$141.25kno data
1.5yrs
Average Tenure
57yo
Average Age

Experienced Management: 2GT's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Susan Washer
President19.1yrsUS$1.47mno data
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datano datano data
Edward Hurwitz
Independent Director10.1yrsUS$65.23k0%
€ 0
Anne VanLent
Independent Director6.3yrsUS$79.23kno data
Scott Koenig
Independent Chairman of the Board20.7yrsUS$101.50k0%
€ 0
David Birch
Member of Ophthalmology Scientific Advisory Boardno datano datano data
William Aliski
Independent Director4.3yrsUS$78.23k0%
€ 0
Peter Campochiaro
Member of Ophthalmology Scientific Advisory Boardno datano datano data
James Rosen
Independent Director12.8yrsUS$72.34k0%
€ 0
Paul Kaufman
Member of Ophthalmology Scientific Advisory Boardno datano datano data
Stephen Daiger
Member of Ophthalmology Scientific Advisory Boardno datano datano data
Robert Molday
Member of Ophthalmology Scientific Advisory Boardno datano datano data
11.4yrs
Average Tenure
65.5yo
Average Age

Experienced Board: 2GT's board of directors are seasoned and experienced ( 11.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/04 13:05
End of Day Share Price 2022/11/28 00:00
Earnings2022/09/30
Annual Earnings2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Applied Genetic Technologies Corporation is covered by 10 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
Yun ZhongBrean Capital Historical (Janney Montgomery)
Yun ZhongBTIG